These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27061338)

  • 1. Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial.
    Spiridigliozzi GA; Hart SJ; Heller JH; Schneider HE; Baker JA; Weadon C; Capone GT; Kishnani PS
    Am J Med Genet A; 2016 Jun; 170(6):1545-55. PubMed ID: 27061338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
    Heller JH; Spiridigliozzi GA; Crissman BG; Sullivan JA; Eells RL; Li JS; Doraiswamy PM; Krishnan KR; Kishnani PS
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):755-65. PubMed ID: 17201619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series.
    Spiridigliozzi GA; Heller JH; Crissman BG; Sullivan-Saarela JA; Eells R; Dawson D; Li J; Kishnani PS
    Am J Med Genet A; 2007 Jul; 143A(13):1408-13. PubMed ID: 17542008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
    de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
    Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.
    Heller JH; Spiridigliozzi GA; Crissman BG; McKillop JA; Yamamoto H; Kishnani PS
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):517-20. PubMed ID: 21186971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17.
    Kishnani PS; Heller JH; Spiridigliozzi GA; Lott I; Escobar L; Richardson S; Zhang R; McRae T
    Am J Med Genet A; 2010 Dec; 152A(12):3028-35. PubMed ID: 21108390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA
    Goeldner C; Kishnani PS; Skotko BG; Casero JL; Hipp JF; Derks M; Hernandez MC; Khwaja O; Lennon-Chrimes S; Noeldeke J; Pellicer S; Squassante L; Visootsak J; Wandel C; Fontoura P; d'Ardhuy XL;
    J Neurodev Disord; 2022 Feb; 14(1):10. PubMed ID: 35123401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.
    Kishnani PS; Sommer BR; Handen BL; Seltzer B; Capone GT; Spiridigliozzi GA; Heller JH; Richardson S; McRae T
    Am J Med Genet A; 2009 Aug; 149A(8):1641-54. PubMed ID: 19606472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.
    Brawman-Mintzer O; Tang XC; Bizien M; Harvey PD; Horner MD; Arciniegas DB; Raskind M; Johnson-Greene L; Martineau RJ; Hamner M; Rodriguez-Suarez M; Jorge RE; McGarity S; Wortzel HS; Wei Y; Sindowski T; Mintzer J; Kindy AZ; Donovan K; Reda D
    J Neurotrauma; 2021 Jul; 38(14):1943-1952. PubMed ID: 33514274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for chronic cognitive impairment in traumatic brain injury.
    Dougall D; Poole N; Agrawal N
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD009221. PubMed ID: 26624881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
    Muñoz-Moreno JA; Prats A; Moltó J; Garolera M; Pérez-Álvarez N; Díez-Quevedo C; Miranda C; Fumaz CR; Ferrer MJ; Clotet B;
    PLoS One; 2017; 12(8):e0182547. PubMed ID: 28854283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
    Prasher VP; Huxley A; Haque MS;
    Int J Geriatr Psychiatry; 2002 Mar; 17(3):270-8. PubMed ID: 11921156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
    McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R
    Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.